Self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study
Abstract Background We recently reported that self‐evaluation of the incidence and severity of treatment‐related side effects (TSEs) using a National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0‐based questionnaire was feasible and more informative than doctor r...
Main Authors: | , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-09-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.1687 |
id |
doaj-484b3bee40944291884d030fd257ac71 |
---|---|
record_format |
Article |
spelling |
doaj-484b3bee40944291884d030fd257ac712020-11-25T02:22:55ZengWileyCancer Medicine2045-76342018-09-01794339434410.1002/cam4.1687Self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective studyDanilo Galizia0Andrea Milani1Elena Geuna2Rossella Martinello3Celeste Cagnazzo4Manuela Foresto5Virginia Longo6Paola Berchialla7Gianfranca Solinas8Adele Calori9Bruna Grasso10Chiara Volpone11Gisella Bertola12Gisella Parola13Giancarla Tealdi14Piero Luigi Giuliano15Anna Maria Ballari16Massimo Aglietta17Filippo Montemurro18Investigational and Clinical Oncology (INCO) Candiolo Cancer Institute‐FPO, IRCCS Candiolo ItalyInvestigational and Clinical Oncology (INCO) Candiolo Cancer Institute‐FPO, IRCCS Candiolo ItalyInvestigational and Clinical Oncology (INCO) Candiolo Cancer Institute‐FPO, IRCCS Candiolo ItalyInvestigational and Clinical Oncology (INCO) Candiolo Cancer Institute‐FPO, IRCCS Candiolo ItalyClinical Research Office Candiolo Cancer Institute‐FPO, IRCCS Candiolo ItalyMultidisciplinary Day Hospital Candiolo Cancer Institute‐FPO, IRCS Candiolo ItalyAOU Città della Salute e della Scienza di Torino ‐ Presidio Sant’ Anna Turin ItalyUniversity of Turin Turin ItalyAOU Maggiore della Carità ‐ Novara Novara ItalyOspedale Cardinal Massaia ‐ Asti Asti ItalyAzienda Sanitaria Locale ASL CN2‐Alba‐Bra Alba ItalyAzienda Sanitaria Locale Verbano Cusio Ossola ‐ Verbania Verbania ItalyOspedale Civile Ivrea Ivrea ItalyAzienda ASO S. Croce e Carle ‐ Cuneo Cuneo ItalyAOU Città della Salute e della Scienza di Torino ‐ Presidio Molinette COES Turin ItalyAzienda AOU San Luigi Gonzaga ‐ Orbassano Turin ItalyMedical Oncology Candiolo Cancer Institute‐FPO, IRCCS Candiolo ItalyMedical Oncology Candiolo Cancer Institute‐FPO, IRCCS Candiolo ItalyInvestigational and Clinical Oncology (INCO) Candiolo Cancer Institute‐FPO, IRCCS Candiolo ItalyAbstract Background We recently reported that self‐evaluation of the incidence and severity of treatment‐related side effects (TSEs) using a National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0‐based questionnaire was feasible and more informative than doctor reports in patients undergoing standard adjuvant chemotherapy for operable breast cancer. Here, we compare self‐ and doctor‐evaluated day of onset and duration of TSEs in the same population. Patients and methods Six hundred and four patients were enrolled at 11 sites in Italy. CTCAE v4.0 definitions of grade of severity of nausea, vomiting, constipation, anorexia, dysgeusia, diarrhea, fatigue, pain, paresthesia, and dyspnea were translated into Italian and rephrased. Questionnaires were administered after the first and third chemotherapy cycles. At each time‐point, information on TSEs was extracted from the medical charts and compared to patient questionnaires. Results A total of 594 and 573 paired patient and doctor questionnaires were collected after cycles one and three, respectively. TSE duration was significantly longer when reported by patients compared to doctors for six and seven of ten items after cycles one and three, respectively. Due to the combined effect of doctor underreporting of TSE incidence and duration, the mean percentages of cycle days with TSEs were significantly higher for all ten items when based on patient reports. Day of onset could not be evaluated because of insufficient numbers of complete records. Conclusions Self‐reporting TSE duration is feasible using a CTCAE‐derived questionnaire. As doctors tend to underestimate TSE incidence and duration, patient‐reported outcomes should be incorporated into clinical practice, perhaps using eHealth technologies, to harness their potential to better estimate total TSE burden.https://doi.org/10.1002/cam4.1687adjuvant chemotherapybreast cancerchemotherapy‐related side effectscommon toxicity criteria for adverse eventsdurationpatient‐reported outcomes |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Danilo Galizia Andrea Milani Elena Geuna Rossella Martinello Celeste Cagnazzo Manuela Foresto Virginia Longo Paola Berchialla Gianfranca Solinas Adele Calori Bruna Grasso Chiara Volpone Gisella Bertola Gisella Parola Giancarla Tealdi Piero Luigi Giuliano Anna Maria Ballari Massimo Aglietta Filippo Montemurro |
spellingShingle |
Danilo Galizia Andrea Milani Elena Geuna Rossella Martinello Celeste Cagnazzo Manuela Foresto Virginia Longo Paola Berchialla Gianfranca Solinas Adele Calori Bruna Grasso Chiara Volpone Gisella Bertola Gisella Parola Giancarla Tealdi Piero Luigi Giuliano Anna Maria Ballari Massimo Aglietta Filippo Montemurro Self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study Cancer Medicine adjuvant chemotherapy breast cancer chemotherapy‐related side effects common toxicity criteria for adverse events duration patient‐reported outcomes |
author_facet |
Danilo Galizia Andrea Milani Elena Geuna Rossella Martinello Celeste Cagnazzo Manuela Foresto Virginia Longo Paola Berchialla Gianfranca Solinas Adele Calori Bruna Grasso Chiara Volpone Gisella Bertola Gisella Parola Giancarla Tealdi Piero Luigi Giuliano Anna Maria Ballari Massimo Aglietta Filippo Montemurro |
author_sort |
Danilo Galizia |
title |
Self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study |
title_short |
Self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study |
title_full |
Self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study |
title_fullStr |
Self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study |
title_full_unstemmed |
Self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study |
title_sort |
self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: a prospective study |
publisher |
Wiley |
series |
Cancer Medicine |
issn |
2045-7634 |
publishDate |
2018-09-01 |
description |
Abstract Background We recently reported that self‐evaluation of the incidence and severity of treatment‐related side effects (TSEs) using a National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0‐based questionnaire was feasible and more informative than doctor reports in patients undergoing standard adjuvant chemotherapy for operable breast cancer. Here, we compare self‐ and doctor‐evaluated day of onset and duration of TSEs in the same population. Patients and methods Six hundred and four patients were enrolled at 11 sites in Italy. CTCAE v4.0 definitions of grade of severity of nausea, vomiting, constipation, anorexia, dysgeusia, diarrhea, fatigue, pain, paresthesia, and dyspnea were translated into Italian and rephrased. Questionnaires were administered after the first and third chemotherapy cycles. At each time‐point, information on TSEs was extracted from the medical charts and compared to patient questionnaires. Results A total of 594 and 573 paired patient and doctor questionnaires were collected after cycles one and three, respectively. TSE duration was significantly longer when reported by patients compared to doctors for six and seven of ten items after cycles one and three, respectively. Due to the combined effect of doctor underreporting of TSE incidence and duration, the mean percentages of cycle days with TSEs were significantly higher for all ten items when based on patient reports. Day of onset could not be evaluated because of insufficient numbers of complete records. Conclusions Self‐reporting TSE duration is feasible using a CTCAE‐derived questionnaire. As doctors tend to underestimate TSE incidence and duration, patient‐reported outcomes should be incorporated into clinical practice, perhaps using eHealth technologies, to harness their potential to better estimate total TSE burden. |
topic |
adjuvant chemotherapy breast cancer chemotherapy‐related side effects common toxicity criteria for adverse events duration patient‐reported outcomes |
url |
https://doi.org/10.1002/cam4.1687 |
work_keys_str_mv |
AT danilogalizia selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy AT andreamilani selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy AT elenageuna selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy AT rossellamartinello selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy AT celestecagnazzo selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy AT manuelaforesto selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy AT virginialongo selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy AT paolaberchialla selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy AT gianfrancasolinas selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy AT adelecalori selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy AT brunagrasso selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy AT chiaravolpone selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy AT gisellabertola selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy AT gisellaparola selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy AT giancarlatealdi selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy AT pieroluigigiuliano selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy AT annamariaballari selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy AT massimoaglietta selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy AT filippomontemurro selfevaluationofdurationofadjuvantchemotherapysideeffectsinbreastcancerpatientsaprospectivestudy |
_version_ |
1724861099274141696 |